Engaging Our Patients to Build Resilience and Reduce Stigma | ATSH Virtual Learning Session 2 | November 10, 2021 | 12 – 4 PM PT
Navigation: About | Preparing for the Event | Event Speakers | Resources | Recordings
about
This event is for participants of the ATSH: Learning Collaborative and any other clinic team members that interact with MAT work. Please join us for a highly interactive and practical 4-hour session addressing topics that are timely and important for your MAT programs.
By the end of this meeting, participants will have:
- Understood the challenges and strategies associated with treating SUD in an era of fentanyl;
- Discussed approaches to patient engagement & retention, harm reduction, and trauma informed care during breakout groups;
- Spent time with your team to develop plans and next steps for content learned; and
- Connected with some new colleagues in the cohort.
Preparing for the event
Pre-Work:
- Brush up on your QI skills – Watch this video What is PDSA and Why Use It? (To access the video, log into the CCI Academy)
- Read: The Future of Fentanyl and Other Synthetic Opioids. Pardo, B, et. al. RAND Corporation, 2019
Order Your Snack Basket: We are offering your teams a delicious snack and beverage basket to enjoy during or after the session. Team Leads have received an email with instructions to order the snack basket. Order now! Questions? Email Lydia.
Ask Your Questions In Advance: Dr. David Kan will be discussing treating SUD in an era of fentanyl. He is interested in understanding the fentanyl challenges your teams are encountering to provide tailored insights and approaches during our session. Submit questions here.
EVENT SPEAKERS
Our speakers are below. Read their biographies.
- Katie Bell, MSN RN-BC CARN PHN, ATSH Coach
- Ginny Eck, ATSH Coach
- David Kan, MD, DFASAM, Bright Heart Health
- Dominique McDowell, RLPS, SUDCC II, ATSH Coach
- Emma Roberts, National Harm Reduction Coalition
Resources
1. Agenda
2. Slides + Handouts:
- Full Session Slide Deck
- Plenary: Medications for Opioid Use Disorder in an Era of Fentanyl | David Kan, M.D., Bright Heart Health
- Patient Engagement and Retention | Ginny Eck and Dominique McDowell, RLPS, SUDCII
- Breakout: Cultivating Resilience: Connecting the Dots for Trauma-Informed MAT Care | Katie Bell, MSN RN-BC CARN PHN
- Handouts: Southwick Self-Interview + Resilience Questionnaire
- Breakout: Foundations of Harm Reduction | Emma Roberts, National Harm Reduction Coalition
3. Fentanyl Readings
-
- The Future of Fentanyl and Other Synthetic Opioids. Pardo, B, et. al. RAND Corporation, 2019
- High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder. Herring AA, et al. 2021 July
- “Everything is not right anymore”: Buprenorphine experiences in an era of illicit fentanyl. Silverstein SM, et al. 2019 Dec
- Treatment of Opioid Use Disorder Attributed to Fentanyl With High-Dose Buprenorphine: A Case Report. Baca-Atlas MH, et al. 2021 Jan/Feb
- High Dose Buprenorphine for Treatment of High Potency Opioid Use Disorder. Danilewitz M, et al. Drug Alcohol Rev. 2020 Feb;39(2):135-137.
- Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method. Hämmig R, et al. 2016 Jul
4. QI Skills
- Check out the ABCs of QI video series on the CCI Academy. The four videos in Short Course 5 cover the topic of Using PDSAs to Test Change Ideas. Watch the videos by logging into the CCI Academy.
Recordings
-
- Plenary: Medications for Opioid Use Disorder in an Era of Fentanyl | David Kan, M.D., Bright Heart Health
-
- Patient Engagement and Retention | Ginny Eck and Dominique McDowell, RLPS, SUDCII
-
- Breakout: Cultivating Resilience: Connecting the Dots for Trauma-Informed MAT Care | Katie Bell, MSN RN-BC CARN PHN
- Breakout: Foundations of Harm Reduction | Emma Roberts, National Harm Reduction Coalition